Allergy Therapeutics PLC (GB:AGY)
LSE:AGY

Allergy Therapeutics (AGY) Share Price & Analysis

0 Followers

AGY Stock Chart & Stats

Day’s Range0p - 0p
52-Week Range4.00p - 23.00p
Previous Close6.25p
Volume0.00
Average Volume (3M)N/A
Market Cap
£42.44M
Enterprise Value3.25B
Total Cash (Recent Filing)£20.52M
Total Debt (Recent Filing)£10.53M
Price to Earnings (P/E)-3.2
Beta0.30
Jun 30, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding641,772,718
10 Day Avg. Volume183,019
30 Day Avg. VolumeN/A
Standard Deviation0.16
R-Squared0.09
Alpha0.00375
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)5.50
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0


Allergy Therapeutics News


Financials

Annual

AGY FAQ

What was Allergy Therapeutics PLC’s price range in the past 12 months?
Allergy Therapeutics PLC lowest share price was 4.00p and its highest was 23.00p in the past 12 months.
    What is Allergy Therapeutics PLC’s market cap?
    Currently, no data Available
    When is Allergy Therapeutics PLC’s upcoming earnings report date?
    Allergy Therapeutics PLC’s upcoming earnings report date is Jun 30, 2023 which is in 27 days.
      How were Allergy Therapeutics PLC’s earnings last quarter?
      Allergy Therapeutics PLC released its earnings results on Sep 29, 2022. The company reported -0.03p earnings per share for the quarter, missing the consensus estimate of -0.02p by -0.01p.
        Is Allergy Therapeutics PLC overvalued?
        According to Wall Street analysts Allergy Therapeutics PLC’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Allergy Therapeutics PLC pay dividends?
          Allergy Therapeutics PLC does not currently pay dividends.
          What is Allergy Therapeutics PLC’s EPS estimate?
          Allergy Therapeutics PLC’s EPS estimate is -£0.01.
            How many shares outstanding does Allergy Therapeutics PLC have?
            Allergy Therapeutics PLC has 679,104,600 shares outstanding.
              What happened to Allergy Therapeutics PLC’s price movement after its last earnings report?
              Allergy Therapeutics PLC reported an EPS of -0.03p in its last earnings report, missing expectations of -0.02p. Following the earnings report the stock price went up 2.703%.
                Which hedge fund is a major shareholder of Allergy Therapeutics PLC?
                Currently, no hedge funds are holding shares in GB:AGY

                ---

                Allergy Therapeutics Stock Smart Score

                This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                Learn more about TipRanks Smart Score

                Company Description

                Allergy Therapeutics PLC

                Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergy with aluminium-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany and other countries.

                ---

                Forecast EPS vs Actual EPS


                Similar Stocks
                Company
                Price & Change
                Follow
                Advanced Medical Solutions
                Redx Pharma
                Animalcare
                Futura Medical

                Popular Stocks

                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis